In conclusion, the use of commercial multi-gene panels to confirm syndromic associations with cancer is problematic and the results of these should not in particular be used to refute the far better evidence from cohort studies6,7 backed up by biology6,8,9 in NF1. This evidence concerns the gene NF1 and cancer.